帕拉米韦治疗流感的临床研究进展

发布时间：2018-07-06 21:19

  本文选题：帕拉米韦 + 流感　； 参考：《中国新药杂志》2017年08期

【摘要】：目的:为帕拉米韦的临床合理应用提供参考。方法:收集国外关于帕拉米韦用于治疗流感病毒的临床有效性和安全性研究文献,进行归纳和综述。结果:共检索到303篇文献记录,最终筛选出10篇文献。研究结果显示:帕拉米韦对健康受试者具有良好的安全性和耐受性;帕拉米韦治疗无并发症的住院流感患者疾病持续时间为38.7 h(400 mg组)和45.5 h(200 mg组),治疗感染流感病毒的高危患者缓解流感症状的平均时间为68.6 h;治疗季节性甲型H3N2流感,帕拉米韦组患者体温下降至37.5℃以下所用的时间最短(均值17.0 h);对老人、儿童、孕妇以及患有基础疾病的流感患者,帕拉米韦的疗效与其他神经氨酸酶抑制剂相比更显著。结论:帕拉米韦的耐受性好,不易出现耐药,且安全性较好,是目前极具应用价值的抗流感新药。
[Abstract]:Objective: to provide reference for rational clinical application of paramivir. Methods: the literature on the clinical efficacy and safety of paramivir in the treatment of influenza virus was collected and summarized. Results: a total of 303 literature records were retrieved and 10 articles were screened out. The results showed that paramivir had good safety and tolerance to healthy subjects. The duration of inpatients with influenza without complications was 38.7 h (400 mg group) and 45.5 h (200 mg group), and the average time of relieving influenza symptoms in high-risk patients infected with influenza virus was 68.6 h. The effect of paramivir on the elderly, children, pregnant women and influenza patients with underlying diseases was significantly higher than that of other neuraminidase inhibitors in the paramivir group, which took the shortest time to fall below 37. 5 鈩，

本文编号：2104112